uniQure N.V. announced on January 8, 2025, the pricing of its underwritten public offering, consisting of 4,411,764 ordinary shares at a public offering price of $17.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses.
The company has also granted the underwriters a 30-day option to purchase up to 661,764 additional ordinary shares at the public offering price. The offering is anticipated to close on or about January 10, 2025, subject to customary closing conditions.
This capital infusion is crucial for uniQure as it continues to advance its pipeline of gene therapies, particularly with the ongoing development and regulatory preparations for AMT-130 in Huntington's disease. The funds will support the company's operational needs and clinical milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.